Physician profile
Unknown Bilori
NPI 1760762090
$4,986.96
in general payments reported to CMS, 2019-2025
26 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $98.48 · 2021: $412 · 2022: $684 · 2023: $911 · 2024: $1,656 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $936.49 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $840.80 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $501.22 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $445.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $390.04 | 2023-2025 | |
| Lilly USA, LLC | $299.21 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $278.33 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $252.13 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $159.16 | 2020-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.27 | 2022-2025 | Xifaxan |
| Heron Therapeutics, INC. | $127.10 | 2024 | Zynrelef |
| Merck Sharp & Dohme LLC | $114.83 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $94.68 | 2022-2024 | Eliquis |
| Novo Nordisk INC | $77.74 | 2019-2023 | Ozempic, Rybelsus |
| Impel Pharmaceuticals INC. | $46.40 | 2023 | Trudhesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.92 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.91 | 2022 | |
| Bausch Health US, LLC | $37.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $24.22 | 2025 | Voquezna |
| Alkermes, INC. | $22.62 | 2024 | Vivitrol |
| Amneal Pharmaceuticals LLC | $21.78 | 2024 | Unithroid |
| Sumitomo Pharma America, INC. | $20.14 | 2023 | Gemtesa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.54 | 2025 | Lifevest |
| Intra-Sana Laboratories | $14.55 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Braeburn INC. | $14.15 | 2024 | Brixadi |
| Almatica Pharma LLC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Unknown Bilori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.